Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

British Journal of Cancer

Volumn 88, Issue 6, 2003, Pages 814-821

  Schellens, J H M ^a,b   Planting, A S Th ^c   Van Zandwijk, N ^a   Ma, J ^c   Maliepaard, M ^a   Van Der Burg, M E L ^c   De Boer Dennert, M ^c   Brouwer, E ^c   Van Der Gaast, A ^c   Van Den Bent, M J ^c   Verweij, J ^c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Adaptive intrapatient dose adjustment; Cisplatin; Nonsmall cell lung cancer; Pharmacokinetics; Platinum DNA adducts

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DNA ADDUCT; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEASIBILITY STUDY; FEMALE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0242416647     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600794     Document Type: Article

References (41)

1. Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P (1993) Randomized trail of etoposie and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multinstitutional study. J Clin Oncol 11: 593-595
2. Common Toxicity Criteria (1998) Cancer Therapy Evaluation Program, Division of Cancer Treatment. National Cancer Institute, Bethesda MD, USA
3. Eastman A, Schulte N (1988) Enhanced DNA repair as a mechanism of resistance to cis-diaminedichloroplatinum (II). Biochemistry 27: 4730-4734
4. Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R (1999) Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer 85: 855-863
5. Fukuoka M, Negoro S, Masuda N, Kusoni Y, Matsui K, Ryu S, Takifuji N, Kudoh S, Takada M, (1992) Mitomycin C vindesine and cisplatin in advanced non-small cell lung cancer: a phase II study. Am J Clin Oncol 15: 18-22
6. Gandara DR, Wold HG, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J, De Gregorio MW (1989) Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and 8 high-dose regimen. J Natl Cancer Inst 81: 790-794
7. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP (1993) Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873-878
8. Gralla RG, Casper ES, Kelsen DP, Braun Jr DW, Dukeman ME, Martini N, Young CW, Golbey RB (1981) Cisplatin plus vindesine combination chemotherapy for advanced carcinoma of the lung. A randomized trial investigating two dosage schedules. Ann Intern Med 95: 414-420
9. Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR on behalf of the Gruppo Oncologico Centro-Sud-Isole (1996) Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small cell lung cancer: a phase III multicentre randomized trial. Ann Oncol 7: 821-826.
10. Kanzawa F, Nishio K, Fukuoka K, Fukuda M, Kunimoto T, Saijo M (1997) Evaluation of synergism by a novel three-dimensional mode for the combined action of cisplatin and etoposide on the growth of a human small-cell lung cancer cell line, SBC3. In J Cancer 71: 311-319
11. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM (1992) Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329-333
12. Klastersky J (1986) Therapy with cisplatin and etoposide for non-small cell lung cancer. Semin Oncol 13: 104-114
13. Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P, Bonduelle Y, Mairesse M, Michiels T, Thiriaux J, Mommen P, Dalesio O and the EORTC Lung Cancer Working Party (1986) A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 4: 1780-1786
14. Krarup-Hansen A, Hansen HH (1991) Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 28: 319-330
15. Lippe P, Gummarello D, Monterubbianesi MC, Silva RR, Giuliodori L, Mari D, Santo, Pasini F, Cetto GL, Rossi D, Porfiri E, Cascinu S, Cellerino R. (1999) Weekly gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase II study. Ann Oncol 10: 217-221
16. Liu RJ (1993) Chemotherapy outcomes in advanced non-small cell lung carcinoma. Sem Oncol 20: 296-301
17. Loehrer PJ, Einhorn LH (1984) Drugs five years later. Cisplatin. Ann Intern Med 100: 704-713
18. Ma J, Verweij J, Planting AS, de Boer-Dennert M, van Ingen HE, van der Burg ME, Stoter G, Schellens JH (1995) Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. 71: 512-517
19. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909.
20. Ozols RF, Young RC (1984) Chemotherapy of ovarian cancer. 11: 251-263
21. Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1993) Phase I/II study of a short course of weekly cisplatin in patients with advanced tumors. Br J Cancer 68: 789-792
22. Planting AST, Schellens JHM, Goey SH, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1994) Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 5: 373-374
23. Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1995a) Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. Ann Oncol 6: 190-192.
24. Planting AST, van der Burg MEL, Goey SH, Schellens JHM, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1995b) Phase II study of a short course of weekly high-dose cisplatin combined with long term oral etoposide in pleural mesothelioma. Ann Oncol 6: 613-615
25. Planting AST (1996) Weekly scheduling of cisplatin: feasibility, efficacy and perspective. Thesis, Erasmus University Rotterdam
26. Planting AST, van der Burg MEL, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1996a) Phase II study of a short course of weekly high-dose cisplatin combined with long term oral etoposide in metastatic colorectal cancer. Br J Cancer 73: 1265-1267
27. Planting AST, van der Burg MEL, Goey SH, Schellens JHM, Vecht C, de Boer-Dennert M, Stoter G, Verweij J (1996b) Phase II study of a short course of weekly high-dose cisplatin combined with long term oral etoposide in metastatic malignant melanoma. Eur J Cancer 32A: 2026-2028
28. Planting AST, de Mulder PH, de GraeffA, Verweij J (1997) Phase II study of weekly high-dose cisplatin for six cycles in patients with advanced squamous cell carcinoma of the head and neck. Eur J Cancer 33: 61-65
29. Planting AST, Catimel G, de Mulder PH, de Graeff A, Hoppener F, Verweij J, Oster W, Vermorken JB (1999) Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol 10: 693-700.
30. Ramanathan RK, Belani CP (1997) Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Sem in Oncol 24: 440-454
31. Reece PHA, Stafford I, Russel J, Khan M, Fill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5: 304-309
32. Reece PHA, Stafford I, Abbott RL, Anderson C, Denham J, Freeman S, Morris RG, Gill PG, Olweny CL (1989) Two versus 24-hours infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol 7: 270-275
33. Ruckdeschel JC (1990) Is chemotherapy for metastatic non-small cell lung cancer 'worth it'? J Clin Oncol 8: 1293-1296
34. Schellens JHM, Ma J, Planting AST, van der Burg MEL, van Meerten E, de Boer-Dennert M, Schmitz PIM, Stoter G, Verweij J (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumor response in patients with solid tumors. Br J Cancer 73: 1569-1575
35. Sculier JP, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, van Cutsem O, Schmerber J, Giner V, Berchier MC, Sergysels R, Mommen P, Klastersky J for the European Lung Cancer Working Party (1994) Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer. Eur J Cancer 30A: 1342-1347
36. Souquet PJ, Chauvin F, Boissel JP, Bernard JP (1995) Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer (Suppl 1): S147-S154
37. Tsai CM, Gazdar AF, Venzon DJ, Steinberg SM, Dedrick RL Mushine JL, Kramer BS (1989) Lack of in vitro synergy between etoposide and cis-diaminedichloroplatinum (II), Cancer Res 49: 2390-2397
38. Wampler GL, Carter JR WH, Campbell ED, Keefe PA (1992) Relationships between various uses of antineoplastic drug-interaction terms. Cancer Chemother Pharmacol 31: 111
39. WHO (1979) Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization.
40. Wozniak AJ, Crowley JJ, Stanley P, Balcerzak P, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 16: 2459-2465
41. Van Zandwijk N, Giaccone G (1996) Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 8: 120-125